G1/22 and G2/22: changed priorities ahead at the EPO?
Two years after dismissing Broad Institute’s appeal against revocation of a CRISPR patent, the EPO will revisit questions on examination and validity of priority claims. Sheena Linehan of Potter Clarkson asks why US and European practice has again collided
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: